EUVIMEDEUVIMED entdecken
Open Access

Sample size determination for randomized decentralized clinical trials with longitudinal outcomes

Chunyi Zhang iD, Ying Yuan iD, Ruitao Lin iD, Suyu Liu iD

Biometrics · 07.10.2026 · 82 (4)

DOI: 10.1093/biomtc/ujag178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, online erschienen am 31.10.2026. Verfasst von Chunyi Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Decentralized clinical trials (DCTs) offer significant advantages in enhancing trial accessibility, reducing patient burden, and improving population representativeness. These benefits are particularly pronounced in longitudinal trials, where patient outcomes are measured repeatedly over time. However, existing literature lacks appropriate sample size formulas tailored to longitudinal DCTs, which must account for heterogeneous measurement sources and increased uncertainty introduced by decentralized data collection. We propose a unified sample size calculation method for randomized longitudinal DCTs under the generalized linear model framework. The proposed formula is available in closed form and flexibly accommodates a variety of data collection designs, including the simple hybrid design, where all patients contribute both onsite and offsite data, and the stratified hybrid design, where different patient groups may undergo distinct data collection protocols. We also develop estimation procedures to estimate the unknown parameters and compute the sample statistics. Our method further generalizes to accommodate heterogeneous intraclass correlation coefficients, unequal variances between treatment arms, and varying numbers of data collection types or strata. Extensive simulation studies show that the proposed sample size formula achieves robust control of the type I error rate and maintains the desired power across a wide range of realistic scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicSample SizeLongitudinal StudiesHumansComputer SimulationModels, StatisticalBiometryData Interpretation, StatisticalLinear ModelsResearch Design

Stichwörter der Autor:innen

decentralized clinical trialslongitudinal datapower calculationrepeated measuressample size determination

Autor:innen und Institutionen

  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Chunyi Zhang, Ying Yuan, Ruitao Lin, Suyu Liu

Förderung

  • NLM NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • U.S. Department of Health and Human Services
  • FDA HHS
  • NIDDK NIH HHS
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Zhang, C., Yuan, Y., Lin, R., & Liu, S. (2026). Sample size determination for randomized decentralized clinical trials with longitudinal outcomes. Biometrics, 82(4). https://doi.org/10.1093/biomtc/ujag178

Vancouver

Zhang C, Yuan Y, Lin R, Liu S. Sample size determination for randomized decentralized clinical trials with longitudinal outcomes. Biometrics. 2026;82(4). doi:10.1093/biomtc/ujag178

BibTeX
@article{Zhang2026,
  author = {Zhang, Chunyi and Yuan, Ying and Lin, Ruitao and Liu, Suyu},
  title = {Sample size determination for randomized decentralized clinical trials with longitudinal outcomes},
  journal = {Biometrics},
  year = {2026},
  volume = {82},
  number = {4},
  doi = {10.1093/biomtc/ujag178}
}
Kostenlos starten →